June 25, 2019 / 5:31 AM / 6 months ago

BRIEF-Erytech Announces Immune Modulation Strategic Collaboration With SQZ Biotechnologies

June 25 (Reuters) - ERYTECH PHARMA SA:

* ERYTECH ANNOUNCED ON MONDAY IT HAS ENTERED INTO AN AGREEMENT WITH SQZ BIOTECHNOLOGIES TO ADVANCE NOVEL RBC-BASED THERAPEUTICS FOR IMMUNE MODULATION

* ERYTECH HAS GRANTED TO SQZ AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP ANTIGEN-SPECIFIC IMMUNE MODULATING THERAPIES EMPLOYING RBC-BASED APPROACHES

* ERYTECH IS ELIGIBLE TO RECEIVE UP TO $57 MLN IN COMBINED UPFRONT AND POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS FOR FIRST PRODUCT SUCCESSFULLY DEVELOPED BY SQZ UNDER THIS AGREEMENT

* ERYTECH ALSO ELIGIBLE TO RECEIVE SALES ROYALTIES, AND UP TO $50 MLN IN COMMERCIAL MILESTONE PAYMENTS RELATED TO EACH ADDITIONAL APPROVED PRODUCT OR APPROVED INDICATION

Source text: bit.ly/2Y7qToI

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below